You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Claims for Patent: 5,980,945


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 5,980,945
Title: Sustained release drug formulations
Abstract:A sustained release drug formulation including: a drug; a biodegradable polymer which is insoluble in water; and an oil vehicle in which both the drug and the polymer are dissolved. The oil vehicle contains 10-100% by volume a pharmaceutically acceptable oil and 0-90% by volume a pharmaceutically acceptable liquid carrier for the drug or the polymer.
Inventor(s): Ruiz; Jean-Marc (Maintenon, FR)
Assignee: Societe de Conseils de Recherches et d\'Applications Scientifique S.A. (Paris, FR)
Application Number:08/584,320
Patent Claims:1. A sustained release drug formulation, said formulation comprising:

a drug;

a biodegradable polymer which is insoluble in water; and

an oil vehicle containing a pharmaceutically acceptable oil which is biodegradable and a pharmaceutically acceptable liquid carrier which dissolves said drug or said polymer, said oil vehicle comprising 10-100% by volume of said oil and 0-90% by volume of said liquid carrier;

wherein both said drug and said polymer are dissolved in said oil vehicle, provided that said polymer is not over 75,000 daltons.

2. A formulation of claim 1, wherein the amount of said polymer is 1-500 mg per ml of said oil vehicle.

3. A formulation of claim 2, wherein the amount of said polymer is 15-300 mg per ml of said oil vehicle.

4. A formulation of claim 3, wherein the molecular weight of said polymer is 1,000-75,000 daltons.

5. A formulation of claim 4, wherein said oil is corn oil, cottonseed oil, peanut oil, sesame oil, castor oil, or a mixture thereof.

6. A formulation of claim 1, wherein said polymer is made of a monomer selected from .epsilon.-caprolactone, lactic acid, glycolic acid, and a combination thereof.

7. A formulation of claim 6, wherein the molecular weight of said polymer is 1,000-75,000 daltons.

8. A formulation of claim 7, wherein said oil is corn oil, cottonseed oil, peanut oil, sesame oil, castor oil, or a mixture thereof.

9. A formulation of claim 1, wherein said oil is corn oil, cottonseed oil, peanut oil, sesame oil, castor oil, or a mixture thereof.

10. A formulation of claim 1, wherein said oil vehicle further comprises a pharmaceutically acceptable ester or polyether to facilitate dissolution of said drug or polymer, said ester or polyether constituting 0.1-90% by volume of said oil vehicle.

11. A formulation of claim 10, wherein said ester or polyether is benzyl benzoate, polyethylene glycol, or a mixture thereof.

12. A formulation of claim 11, wherein said oil vehicle further comprises a pharmaceutically acceptable surfactant.

13. A formulation of claim 10, wherein said oil vehicle further comprises a pharmaceutically acceptable surfactant.

14. A formulation of claim 1, wherein said oil vehicle further comprises a pharmaceutically acceptable surfactant.

15. A formulation of claim 1, wherein said drug is a peptide.

16. A formulation of claim 15, wherein said peptide is a somatostatin agonist or an LHRH agonist.

17. A formulation according to claim 16 wherein the LHRH agonist is p-Glu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH.sub.2.

18. A formulation according to claim 16 wherein the somatostatin agonist is D-Nal-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH.sub.2.

19. A formulation according to claim 15 wherein the peptide is selected from the group consisting of growth hormone releasing peptide, bombesin, gastrin releasing peptide, calcitonin, bradykinin, galanin, melanocyte stimulating hormone, growth hormone releasing factor, amylin, adrenomedullin, tachykinins, secretin, parathyroid hormone, enkephalin, endothelin, calcitonin gene releasing peptide, neuromedins, parathyroid related protein, glucagon, neurotensin, adrenocorticotrophic hormone, peptide YY, glucagon releasing peptide, vasoactive intestinal peptide, pituitary adenylated cyclase activating peptide, motilin, substance P, neuropeptide Y and thyrotropin stimulating hormone, or an analog or fragment thereof.

20. A formulation of claim 1, wherein said drug is a steroid.

21. A formulation of claim 20, wherein said steroid is 17-.beta.-hydroxy .phi.estradiol or progesterone.

22. A method of administering to a patient a formulation according to claim 1, comprising administering said formulation parenterally.

Details for Patent 5,980,945

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Nps Pharmaceuticals, Inc. NATPARA parathyroid hormone For Injection 125511 01/23/2015 ⤷  Try a Trial 2039-02-26
Aimmune Therapeutics, Inc. PALFORZIA peanut (arachis hypogaea) allergen powder Powder 125696 01/31/2020 ⤷  Try a Trial 2039-02-26
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.